Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors
Latest Information Update: 20 Aug 2024
Price :
$35 *
At a glance
- Drugs HuMax IL8 (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 06 Jun 2024 Status changed from suspended to recruiting.
- 30 May 2024 Planned End Date changed from 1 Dec 2026 to 31 May 2027.
- 23 May 2024 Status changed from recruiting to suspended (Enrollment to the safety cohort is complete).